Nuo Therapeutics (AURX)
OTHER OTC:AURX
Want to see AURX full AI Analyst Report?
Top Page
Nuo Therapeutics
(OTC:AURX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▼(-50.00% Downside)
Action:Upgraded
Date:06/06/26
The score is primarily weighed down by weak financial performance—persistent losses, cash burn, and negative equity—despite improving revenue and strong gross margins. Technicals are neutral-to-weak with a negative MACD and longer-term moving averages above the current price, and the recent secured debt/warrant structure adds financing and dilution risk.
Positive Factors
Revenue Growth Momentum
Sustained top-line improvement to ~$4.1M TTM with ~24.7% reported growth indicates expanding commercial traction in core wound-healing markets. Durable revenue momentum supports future operating leverage as fixed costs are spread and underpins pathway to scaled profitability if sustained over quarters.
Negative Factors
Negative Shareholders' Equity
Negative shareholders' equity (~-$1.38M TTM) is a structural balance-sheet impairment that weakens solvency and restricts access to attractive financing. Over months this can force costly financing choices, limit strategic flexibility, and heighten bankruptcy or restructuring risk if cash generation does not improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Sustained top-line improvement to ~$4.1M TTM with ~24.7% reported growth indicates expanding commercial traction in core wound-healing markets. Durable revenue momentum supports future operating leverage as fixed costs are spread and underpins pathway to scaled profitability if sustained over quarters.
Read all positive factors
Nuo Therapeutics (AURX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$56.15M
Dividend YieldN/A
Average Volume (3M)2.99K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue Growth155.81%
EPS Growth2.53%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,408,730
10 Day Avg. Volume655
30 Day Avg. Volume2,988
Financial Highlights & Ratios
PEG Ratio-10.00
Price to Book (P/B)-97.44
Price to Sales (P/S)28.13
P/FCF Ratio-81.78
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue11.75
Enterprise Value/Gross Profit17.96
Enterprise Value/Ebitda-22.31
Forecast
1Y Price Target
$3.00Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nuo Therapeutics Business Overview & Revenue Model
Company Description
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacit...
How the Company Makes Money
null...
Nuo Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.13M | 3.31M | 1.37M | 608.52K | 112.25K | 0.00 |
| Gross Profit | 2.70M | 2.22M | 1.06M | 482.43K | 93.04K | 0.00 |
| EBITDA | -2.18M | -2.36M | -2.36M | -3.06M | -3.10M | 0.00 |
| Net Income | -2.38M | -2.51M | -2.32M | -3.17M | -3.03M | -90.67K |
Balance Sheet | ||||||
| Total Assets | 1.95M | 1.85M | 1.19M | 1.88M | 3.05M | 149.93K |
| Cash, Cash Equivalents and Short-Term Investments | 263.83K | 548.95K | 283.71K | 928.68K | 2.05M | 148.43K |
| Total Debt | 898.95K | 97.35K | 164.21K | 255.59K | 335.05K | 0.00 |
| Total Liabilities | 3.33M | 2.80M | 675.80K | 838.73K | 856.02K | 672.47K |
| Stockholders Equity | -1.38M | -956.56K | 513.71K | 1.04M | 2.19M | -522.54K |
Cash Flow | ||||||
| Free Cash Flow | -1.70M | -1.14M | -2.39M | -3.18M | -3.77M | -13.00K |
| Operating Cash Flow | -1.65M | -864.97K | -2.23M | -3.17M | -3.71M | -13.00K |
| Investing Cash Flow | -45.72K | -274.76K | -154.96K | -7.24K | -59.99K | 0.00 |
| Financing Cash Flow | 1.90M | 1.40M | 1.74M | 2.00M | 4.46M | 1.37T |
Nuo Therapeutics Risk Analysis
Nuo Therapeutics disclosed 40 risk factors in its most recent earnings report. Nuo Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $88.03M | -8.71 | -666.47% | ― | -100.00% | 46.40% | |
47 Neutral | $21.55M | -0.34 | ― | ― | ― | ― | |
45 Neutral | $25.25M | -0.24 | 411.46% | ― | -51.03% | -35.20% | |
45 Neutral | $249.86M | -0.69 | 309.79% | ― | -35.61% | -68.92% | |
42 Neutral | $56.15M | -23.49 | 1030.35% | ― | 155.81% | 2.53% |
* Healthcare Sector Average
AURX
Nuo Therapeutics
1.00
-0.58
-36.71%
INO
Inovio Pharmaceuticals
1.09
-1.13
-50.90%
VTGN
VistaGen Therapeutics
0.54
-1.80
-77.05%
CELU
Celularity
0.81
-1.17
-59.04%
SRZN
Surrozen
20.69
11.89
135.11%
Nuo Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Nuo Therapeutics Expands Secured Debt Facility and Warrants
Negative
Jun 3, 2026
On May 29, 2026, Nuo Therapeutics amended and restated its existing loan and security agreement, expanding lender commitments by $400,000 to provide up to $2.0 million in secured debt, with $1.0 million funded in January, $675,000 funded at the Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.